Daiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment of narcolepsy.

Drug conjugates acting as gonadotropin-releasing hormone (GnRH) receptor ligands have been described in a recent Radionetics Oncology Inc. patent. They are reported to be useful for the diagnosis and treatment of cancer.

Work at Karuna Therapeutics Inc. has led to the identification of substituted tetrahydropyrrolo-pyridinone compounds acting as muscarinic M4 receptor agonists and/or positive allosteric modulators.

Oncopia Therapeutics Inc. has patented proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a CREB-binding protein (CREBBP; CBP) and/or histone acetyltransferase KAT3B (P300)-targeting moiety through a linker.

Celgene Corp. has patented sphingosine 1-phosphate S1P5 receptor (EDG8) modulators reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis.

Bolt Biotherapeutics Inc. has designed new antibody-drug conjugates comprising humanized monoclonal antibody trastuzumab targeting HER2 covalently linked to thienoazepine derivatives acting as Toll-like receptor 7 (TLR7) and/or 8 (TLR8) agonists.

Avelos Therapeutics Inc. has discovered new substituted heterocyclic compound derivatives acting as serine/threonine-protein kinase greatwall (MASTL; GWL) inhibitors.

UCB SA has disclosed new interleukin-6 (IL-6) release inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders.

Several Grünenthal GmbH patents describe sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain.

Hansoh Bio LLC has described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer, infections, neurodegeneration, autoimmune disease, immunological disorders, inflammatory conditions and cardiovascular disorders.